Back to results
US 2021/0239715 A1Published application
Assay for the diagnosis of macular degeneration
AssigneeSyracuse University
InventorRobert P. Doyle
Life of this patent
Estimating the term…
Abstract
An assay and kit for detecting N-retinylidene-N-retinylethanolamine (A2E) in a sample that uses a lipid binding protein, such as Saposin B, to capture A2E in the sample and assist in the extraction and measurement of A2E via mass spectroscopy. A2E thus serves as a marker for macular degeneration so that the assay and kit of the invention can be used to detect the presence or severity of macular degeneration.
Claims8
A method of diagnosing a subject as having macular degeneration, comprising the steps of:
- obtaining a sample from the subject;
- adding a quantity of a lipid binding protein to the sample to bind any N-retinylidene-N-retinylethanolamine in the sample;
- and
- incubating the sample and the quantity of the lipid binding protein with an immunoprecipitation substrate having a plurality of antibodies to the lipid binding protein.
1 more element
Dependencies are inferred from the claim text.